Japer Therapeutics Warrants
JSPRW
15 hedge funds and large institutions have $2.97M invested in Japer Therapeutics Warrants in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
6% less funds holding
Funds holding: 16 → 15 (-1)
20% less capital invested
Capital invested by funds: $3.71M → $2.97M (-$737K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
+$472K |
| 2 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$63.9K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$11.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.63K |
| 5 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
-$414K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$256K |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
-$148K |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$107K |
| 5 |
Walleye Capital
New York
|
-$77.5K |
JSPRW Hedge Fund Activity: Q4 2021 in Review
15 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q4 2021, worth a combined $2.97M — down 20% from $3.71M a quarter earlier.
Fund positioning in JSPRW was balanced in Q4 2021: 7 funds opened new positions, 7 closed out, 0 added to existing stakes and 6 trimmed.
The largest buyer was Ionic Capital Management, opening a new position worth an estimated $472K. The largest seller was Owl Creek Asset Management, cutting an estimated $414K.
- 15 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q4 2021, down from 16 in Q3 2021.
- Funds reported $2.97M of Japer Therapeutics Warrants stock for Q4 2021, down 20% quarter-over-quarter.
- 7 funds opened new Japer Therapeutics Warrants positions in Q4 2021 and 7 closed out, a net change of 0 holders.
- The largest Japer Therapeutics Warrants buyer in Q4 2021 was Ionic Capital Management, an estimated $472K added.
- The largest Japer Therapeutics Warrants seller in Q4 2021 was Owl Creek Asset Management, an estimated $414K sold.
Based on aggregated 13F filings for Q4 2021.